From Vitamin K Antagonists to Liver International Normalized Ratio: A Historical Journey and Critical Perspective

Abstract

Adoption of international normalized ratio (INR) to harmonize prothrombin time has greatly improved the safety and effectiveness of vitamin K antagonists (VKA) oral anticoagulant therapy. INR is also a major laboratory variable in calculating the widely used Model for End-Stage Liver Disease (MELD) score for liver transplant organ prioritization. However, since the conventional INR (INR_VKA) is calibrated specifically for VKA patients, its interlaboratory variation has a significant impact on the accuracy of MELD score. Though still requiring further clinical validation in large numbers of waitlisted patients, the alternative liver INR calibrated by using plasma from liver disease patients instead of VKA patients may harmonize the differences and thus more suitable for MELD score calculation. The objective of this article is to review the history of INR, MELD score, and liver INR, and discuss the challenges and solutions of liver INR implementation.

Keywords

prothrombin time - PT - INR - ISI - liver disease - warfarin - vitamin K antagonist - liver transplant - MELD score

• References

• 1 Schofield FW. Damaged sweet clover: the cause of a new disease in cattle simulating hemorrhagic septicemia and blackleg. J Am Vet Med Assoc 1924; 64: 553-575
• 2 Campbell AH, Smith WK, Roberts WL, Link KP. Studies on the hemorrhagic sweet clover disease. IV. The isolation and crystallization of the hemorrhagic agent. J Biol Chem 1941; 138: 21-33
• 3 Allen EV, Barker NW, Waugh JM. A preparation from spoiled sweet clover (3,3′-methylene-bis-[4-hydroxycoumarin]) which prolongs coagulation and prothrombin time of the blood: a clinical study. JAMA 1942; 120 (13) 1015-1021
• 4 Link KP. The discovery of dicumarol and its sequels. Circulation 1959; 19 (1) 97-107
• 5 Quick AJ. The prothrombin time in hemophilia and in obstructive jaundice. J Biol Chem 1935; 109: 73-74
• 6 Quick AJ. The development and use of the prothrombin tests. Circulation 1959; 19 (1) 92-96
• 7 Sise HS, Lavelle SM, Adamis D, Becker R. Relation of hemorrhage and thrombosis to prothrombin during treatment with coumarin-type anticoagulants. N Engl J Med 1958; 259 (6) 266-271
• 8 Verstraete M, Clark PA, Wright IS. Use of different tissue thromboplastins in the control of anticoagulant therapy. Circulation 1957; 16 (2) 213-226
• 9 Poller L, Taberner DA. Dosage and control of oral anticoagulants: an international collaborative survey. Br J Haematol 1982; 51 (3) 479-485
• 10 Poller L. International Normalized Ratios (INR): the first 20 years. J Thromb Haemost 2004; 2 (6) 849-860
• 11 Smith RE. The INR: a perspective. Semin Thromb Hemost 1997; 23 (6) 547-549
• 12 Kirkwood TB. Calibration of reference thromboplastins and standardisation of the prothrombin time ratio. Thromb Haemost 1983; 49 (3) 238-244
• 13 Organisation WH. Requirements for thromboplastins and plasma used to control oral anticoagulant therapy (requirements for biological substances no.30, revised 1982). WHO Expert Committee on Biological Standardization Thirty-Third Report Annexure 3. WHO Technical Report Series, No. 687. Geneva, Switzerland: World Health Organization; 1983
• 14 Tange JI, Grill D, Koch CD , et al. Local verification and assignment of mean normal prothrombin time and International Sensitivity Index values across various instruments: recent experience and outcome from North America. Semin Thromb Hemost 2014; 40 (1) 115-120
• 15 Favaloro EJ, Adcock DM. Standardization of the INR: how good is your laboratory's INR and can it be improved?. Semin Thromb Hemost 2008; 34 (7) 593-603
• 16 WHO Expert Committee on Biological Standardization. WHO Expert Committee on Biological Standardization. World Health Organ Tech Rep Ser 1999; 889: i-vi , 1–111
• 17 Shahangian S, Labeau KM, Howerton DA. Prothrombin time testing practices: adherence to guidelines and standards. Clin Chem 2006; 52 (5) 793-794
• 18 Kamath PS, Wiesner RH, Malinchoc M , et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33 (2) 464-470
• 19 Wiesner R, Edwards E, Freeman R , et al; United Network for Organ Sharing Liver Disease Severity Score Committee. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124 (1) 91-96
• 20 Jung GE, Encke J, Schmidt J, Rahmel A. [Model for end-stage liver disease. New basis of allocation for liver transplantations]. Chirurg 2008; 79 (2) 157-163
• 21 Trotter JF, Brimhall B, Arjal R, Phillips C. Specific laboratory methodologies achieve higher model for endstage liver disease (MELD) scores for patients listed for liver transplantation. Liver Transpl 2004; 10 (8) 995-1000
• 22 Porte RJ, Lisman T, Tripodi A, Caldwell SH, Trotter JF ; Coagulation in Liver Disease Study Group. The International Normalized Ratio (INR) in the MELD score: problems and solutions. Am J Transplant 2010; 10 (6) 1349-1353
• 23 Trotter JF, Olson J, Lefkowitz J, Smith AD, Arjal R, Kenison J. Changes in international normalized ratio (INR) and model for endstage liver disease (MELD) based on selection of clinical laboratory. Am J Transplant 2007; 7 (6) 1624-1628
• 24 Gatt A. Global Assays of Coagulation in Anticoagulation, Thrombotic Disorders and Liver Disease. Sheffield, UK: University of Sheffield; 2012
• 25 Gatt A, Riddell A, Calvaruso V, Tuddenham EG, Makris M, Burroughs AK. Enhanced thrombin generation in patients with cirrhosis-induced coagulopathy. J Thromb Haemost 2010; 8 (9) 1994-2000
• 26 Tripodi A, Salerno F, Chantarangkul V , et al. Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests. Hepatology 2005; 41 (3) 553-558
• 27 Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med 2011; 365 (2) 147-156
• 28 Wada H, Usui M, Sakuragawa N. Hemostatic abnormalities and liver diseases. Semin Thromb Hemost 2008; 34 (8) 772-778
• 29 Francis JL, Armstrong DJ. Acquired dysfibrinogenaemia in liver disease. J Clin Pathol 1982; 35 (6) 667-672
• 30 Tripodi A, Chantarangkul V, Primignani M , et al. The international normalized ratio calibrated for cirrhosis (INR(liver)) normalizes prothrombin time results for model for end-stage liver disease calculation. Hepatology 2007; 46 (2) 520-527
• 31 Bellest L, Eschwège V, Poupon R, Chazouillères O, Robert A. A modified international normalized ratio as an effective way of prothrombin time standardization in hepatology. Hepatology 2007; 46 (2) 528-534
• 32 Sermon AM, Smith JM, Maclean R, Kitchen S. An International Sensitivity Index (ISI) derived from patients with abnormal liver function improves agreement between INRs determined with different reagents. Thromb Haemost 2010; 103 (4) 757-765
• 33 Riddell AF, Calvaruso V, Tuddenham EG, Burroughs A, Gatt A. A pragmatic approach for the measurement of the INR in liver patients. J Thromb Haemost 2009; 7: abstract 10-6
• 34 Tripodi A, Chantarangkul V, Primignani M , et al. Point-of-care coagulation monitors calibrated for the international normalized ratio for cirrhosis (INRliver) can help to implement the INRliver for the calculation of the MELD score. J Hepatol 2009; 51 (2) 288-295
• 35 Tripodi A. How to implement the modified international normalized ratio for cirrhosis (INR(liver)) for model for end-stage liver disease calculation. Hepatology 2008; 47 (4) 1423-1424 , author reply 1424
• 36 Marlar RA. Determining the model for end-stage liver disease with better accuracy: neutralizing the international normalized ratio pitfalls. Hepatology 2007; 46 (2) 295-296
• 37 Tripodi A, Baglin T, Robert A, Kitchen S, Lisman T, Trotter JF ; Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Reporting prothrombin time results as international normalized ratios for patients with chronic liver disease. J Thromb Haemost 2010; 8 (6) 1410-1412
• 38 Heuman DM, Mihas AA, Habib A , et al. MELD-XI: a rational approach to “sickest first” liver transplantation in cirrhotic patients requiring anticoagulant therapy. Liver Transpl 2007; 13 (1) 30-37
• 39 Izumi S, Langley PG, Wendon J , et al. Coagulation factor V levels as a prognostic indicator in fulminant hepatic failure. Hepatology 1996; 23 (6) 1507-1511
• 40 Leise MD, Kim WR, Kremers WK, Larson JJ, Benson JT, Therneau TM. A revised model for end-stage liver disease optimizes prediction of mortality among patients awaiting liver transplantation. Gastroenterology 2011; 140 (7) 1952-1960
• 41 Owren PA. Thrombotest. A new method for controlling anticoagulant therapy. Lancet 1959; 2 (7106) 754-758
• 42 Magnusson M, Sten-Linder M, Bergquist A , et al. The international normalized ratio according to Owren in liver disease: interlaboratory assessment and determination of international sensitivity index. Thromb Res 2013; 132 (3) 346-351
• 43 Gatt A, Burroughs AK. The Owren INR in liver disease: a way towards standardisation?. Thromb Res 2013; 132 (3) 327-328
• 44 Kim WR, Biggins SW, Kremers WK , et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med 2008; 359 (10) 1018-1026